文档下载 文档下载导航
设为首页 | 加入收藏
搜索 请输入内容:  
 导航当前位置: 文档下载 > 所有分类 > 医药卫生 > 临床医学 > 替米沙坦对急性卒中预后复发的作用
侵权投诉

替米沙坦对急性卒中预后复发的作用

3544Stroke

Table2.

Day7

November2009

HemodynamicEffectsonTreatmentatDays7,30,and90AfterEnrollment

Telmisartan(n 647)

Placebo(n 713)

542(76.0)141.4(17.0)81.6(11.0)59.7(14.7)74.2(10.8)10523(2070)674(94.5)1.04(1.03)267(37.5)231(32.4)151(21.2)50(7.0)12(1.7)2(0.3)142.6(18.6)83.1(11.2)59.5(14.9)664(93.1)140.3(19.0)81.5(11.2)58.7(15.9)

Difference(95%CI)

…6.1(4.0,8.2)3.2(1.8,4.5)2.9(1.1,4.7) 0.2( 1.5,1.2)466(210,723)

…0.08(0.99,1.07)

………………6.9(4.8,9.0)3.6(2.3,4.8)3.3(1.7,5.0)

…5.8(3.6,8.0))2.4(1.1,3.6)3.5(1.7,5.2)

P… 0.0001 0.00010.00170.820.0004…0.14……………… 0.0001 0.0001 0.0001… 0.00010.0002 0.0001

Subjects(%)SBP,mmHgDiastolicBP,mmHgPulsepressure,mmHgHeartrate,bpm

Rate-pressureproduct(SBP.HR)Day30Subjects(%)

Nofnontrialantihypertensives(mean)0(%)12345

SBP,mmHgDiastolicBP,mmHgPulsepressure,mmHgDay90Subjects(%)SBP,mmHgDiastolicBP,mmHgPulsepressure,mmHg

479(74.0)135.3(17.8)78.4(10.8)56.8(14.7)74.3(11.1)10057(1937)612(94.6)0.96(1.03)271(41.9)203(31.4)117(18.1)42(6.5014(2.2)0(0)135.7(20.0)79.6(11.9)56.2(15.1)592(91.5)134.5(19.9)79.2(11.1)55.3(15.4)

N(%)ormean(SD)withdifference(95%CI).Comparisonsby 2testort

替米沙坦对急性卒中预后复发的作用

test.

treatment(telmisartan,placebo)included:hypotension(2vs2),syncope(1vs1),andfalls(2vs1).Noseriousadverseeventsrelatedtoedemaextension,cerebralhemorrhage,MI,orhyperkalemiawererecordedoverthe90days.

Discussion

Theaimofthepresentnonprespecifiedsubgroupanalysiswastoinvestigatethesafety,efficacy,andtolerabilityof

Figure1.ThemRSatday30,comparisonbyMann–WhitneyU,P 0.55(note:mRS 0,nosymptoms;mRS 1,symptoms;mRS 2,slightdisabilitybutindependent;mRS 3,moderatedisabilityrequiringsomehelp;mRS 4,moderatelyseveredis-abilityrequiringsigni canthelpwithactivitiesofdailyliving;mRS 6,dead;nopatientshadmRS 5).ThenumbersintheplotgivethenumberofpatientsineachmRSclassbytreat-mentassignment.

telmisartanwhenstartedintheacutephaseofanischemicstroke;1360patientswererandomizedwithin72hoursoftheonsetofischemiaanddataforthesesubjectsformthebasisofthisreport.Incomparisonwithplacebo,telmisartandidnotalterfunctionaloutcome(assessedusingthemRS)at30daysorotheroutcomes,includingstrokerecurrence,MI,compos-itevascularoutcome,ordeath,eachat90days.Hence,theseresultsmirrorthoseseenacrossthemainstudy,thisbeingneutral,suchthataddingtelmisartantostandardpoststroketreatmentdidnotreducestrokerecurrenceatanaverageof2.5yearsincomparisonwithplacebo.1DespitethefactthatBPatbaselinewasreasonablywellcontrolled(mean,147/84mmHg),telmisartanfurtherreduceditby6to7mmHgand2to4mmHgoverthefirst90daysafterstroke;parallelreductionsinpulsepressureandrate-pressureproductwerealsoseen.Althoughtelmisartandidnotalterstrokerecurrenceineitherthissubgroupanalysisoracrossthewholetrial,1itisnoteworthythatthedirectionofthepointestimateswereinoppositedirections.Inthemaintrial,atrendtoreductionwasapparent(HR,0.95;95%CI,0.86–1.04;P 0.23);aposthocanalysisindicatedthatrecurrencewasnonsignificantlyhigherwithtelmisartanduringthefirst6monthsoftreatment(HR,1.07;95%CI,0.92–1.25)andsignificantlylowerthereafter(HR,0.88;95%CI,0.78–0.99),withasignificanttreatmentbytimeinteraction(P 0.042).1Aswithshort-termtreatmentinthemaintrial,anonsignificantincreaseintheoddsof

上一页第4页

你可能喜欢

热门文档

相关文档

站点地图 | 文档上传 | 侵权投诉 | 手机版
本站所有资源均来自互联网,本站只负责收集和整理,均不承担任何法律责任,如有侵权等其它行为请联系我们.
文档下载 Copyright 2013 doc.guandang.net All Rights Reserved.  -  email